For many researchers, biomarker detection still hits a familiar wall. Standard ELISA methods reach their limits just as biological questions become more interesting—when targets exist at very low concentrations, sample volumes are constrained, or early signals matter most.
Over the past few years, a growing number of labs have shown that it’s possible to push past those limits without abandoning existing workflows.
Across multiple research settings, Exazym’s BOLD signal amplification has demonstrated substantial sensitivity gains using standard immunoassay formats. In one example, cardiac troponin I assays achieved detection down to 0.07 pg/mL—representing up to a 180-fold improvement over conventional ELISA. Similar results have been reported using pre-conjugated antibody pair kits designed to shorten assay development time and reduce optimization effort.
What has been most informative, however, is how researchers have applied the technology in ways not originally anticipated—adapting it to different biomarkers, platforms, and experimental constraints.
From Demonstration to Access
By 2025, the technical question—can this work under real lab conditions—had largely been answered. The more practical question now is access.
Many researchers facing sensitivity challenges still assume that meaningful gains require specialized instruments, new platforms, or extensive re-optimization. In practice, that isn’t always the case. Signal amplification approaches that integrate into existing ELISA workflows can offer an alternative path—one that builds on equipment and antibodies labs already trust.
Closing that awareness gap is an important focus for the year ahead.
Evidence from Independent Workflows
A recent example comes from Gyros Protein Technologies, where researchers presented data at the European Bioanalysis Forum Open Symposium in Barcelona. Their work showed how Exazym’s BOLD signal amplification enhanced three Gyrolab assays—neurofilament light chain (NfL), interleukin-4 (IL-4), and tumor necrosis factor alpha (TNF-α).
The significance lies less in the specific biomarkers than in the context: Exazym was integrated into an automated, microfluidic platform without requiring new instrumentation or a redesign of existing assays. Independent validation in established workflows is often where technologies either prove their practicality—or don’t.
What’s Ahead in 2026
The priority moving forward is straightforward: making it easier for researchers to determine whether Exazym meets their specific detection challenges.
That includes:
- Expanding access through global distribution and research partnerships
- Supporting peer-reviewed publications across different biomarkers and therapeutic areas
- Providing application notes, webinars, and case studies that document real-world use
- Continuing to broaden the range of Exazym kits and formats to support different assay needs
Why This Matters
Ultra-sensitive detection is most useful when it’s practical—when it doesn’t require replacing equipment, re-engineering workflows, or stretching already-tight budgets.
When sensitivity becomes more accessible, researchers can ask different questions: detecting biomarkers earlier, working with smaller sample volumes, or improving confidence at the low end of detection. Those capabilities can influence everything from basic research to drug development and diagnostics.
That’s the opportunity heading into 2026—not as a company milestone, but as a shift in what’s feasible for everyday laboratory work.
If you’re dealing with a biomarker detection challenge and evaluating options, we’re always interested in discussing whether Exazym’s BOLD signal amplification makes sense in your context. Those conversations—grounded in specific assays and real constraints—are where progress actually happens.